More than 10 years ago, Wu et al. observed that castration-resistant prostate cancers (CRPC) displayed lower levels of DAB2IP compared with androgen sensitive cancers, providing the first evidence that correlated its expression with resistance to therapy [5]. Here, DAB2IP is linked to cancer.